Earnings ·
BeOne Medicines Ltd. reported second quarter 2026 financial results on August 5, 2026, posting total global revenues…
BEIGFBeOne Medicines Ltd.
BeOne Medicines Ltd. reported second quarter 2026 financial results on August 5, 2026, posting total global revenues of $1.7 billion, a 30% increase from the prior year. BRUKINSA (zanubrutinib) drove growth with $1.2 billion in sales, while diluted GAAP earnings per ADS reached $2.05. The company raised its full-year 2026 total revenue guidance to $6.6–$6.8 billion and updated operating income expectations accordingly. Business highlights include FDA accelerated approval for BEQALZI (sonrotoclax) in relapsed/refractory mantle cell lymphoma, positive Phase 3 MANGROVE study results for BRUKINSA, and the appointment of three new directors to its Board. BeOne Medicines Ltd. is a global oncology company that discovers and develops innovative cancer treatments.